{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-002421","form_type":"8-K","ticker":"CRNX","cik":"0001658247","company_name":"Crinetics Pharmaceuticals, Inc.","filed_at":"2022-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.661599+00:00","generated_at":"2026-06-27T03:04:31.090027+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Crinetics appoints James Hassard as Chief Commercial Officer","bullets":["James Hassard appointed CCO effective Feb 28, 2022; base salary $425,000, target bonus 40%.","Will receive option to purchase 160,000 shares (25% vest Feb 28, 2023; balance monthly over 3 years).","Hassard brings 30+ years biotech commercial experience; previously CCO at Arrowhead Pharma.","Initial focus on paltusotine Phase 3 PATHFNDR program for acromegaly registration.","Also overseeing commercial readiness for pipeline candidates CRN04777 and CRN04894."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-002421","json":"https://secwatch.observer/filing/0000950170-22-002421.json","markdown":"https://secwatch.observer/filing/0000950170-22-002421.md","text":"https://secwatch.observer/filing/0000950170-22-002421.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658247/000095017022002421/0000950170-22-002421-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658247/000095017022002421/crnx-20220228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T03:04:31.090027+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4cf104fa34","claim":"James Hassard was appointed as Chief Commercial Officer at Crinetics Pharmaceuticals, Inc..","evidence_excerpt":"On March 1, 2022, Crinetics Pharmaceuticals, Inc. (the “Company” or “Crinetics”) announced the appointment of James Hassard as the Company’s Chief Commercial Officer, which was effective as of February 28, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017022002421/0000950170-22-002421-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Commercial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}